Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APRE NASDAQ:ATRA NASDAQ:LITS NASDAQ:TAOX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.95+2.5%$0.82$0.55▼$2.22$11.81M1.481.67 million shs14,835 shsATRAAtara Biotherapeutics$9.99+13.8%$5.39$3.92▼$19.15$85.02M-0.31.23 million shs553,098 shsLITSLite Strategy$1.20-3.6%$1.16$0.95▼$9.00$43.45M0.25350,853 shs132,721 shsTAOXSynaptogenix$5.87-10.5%$5.27$2.12▼$11.98$43.81M1.49171,967 shs77,103 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-5.06%+13.73%+1.47%+45.36%-42.57%ATRAAtara Biotherapeutics+5.28%+79.18%+88.82%+81.78%+20.77%LITSLite Strategy+1.64%+9.73%+6.90%+20.39%+123,999,900.00%TAOXSynaptogenix+1.08%+22.89%+52.68%+74.67%+654,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPREAprea Therapeutics$0.95+2.5%$0.82$0.55▼$2.22$11.81M1.481.67 million shs14,835 shsATRAAtara Biotherapeutics$9.99+13.8%$5.39$3.92▼$19.15$85.02M-0.31.23 million shs553,098 shsLITSLite Strategy$1.20-3.6%$1.16$0.95▼$9.00$43.45M0.25350,853 shs132,721 shsTAOXSynaptogenix$5.87-10.5%$5.27$2.12▼$11.98$43.81M1.49171,967 shs77,103 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPREAprea Therapeutics-5.06%+13.73%+1.47%+45.36%-42.57%ATRAAtara Biotherapeutics+5.28%+79.18%+88.82%+81.78%+20.77%LITSLite Strategy+1.64%+9.73%+6.90%+20.39%+123,999,900.00%TAOXSynaptogenix+1.08%+22.89%+52.68%+74.67%+654,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPREAprea Therapeutics 2.40Hold$4.40361.70% UpsideATRAAtara Biotherapeutics 2.00Hold$9.50-8.65% DownsideLITSLite Strategy 1.00SellN/AN/ATAOXSynaptogenix 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest APRE, ATRA, LITS, and TAOX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026ATRAAtara Biotherapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetHold ➝ Buy$6.00 ➝ $13.005/8/2026ATRAAtara Biotherapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$13.005/7/2026APREAprea Therapeutics OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$5.004/21/2026TAOXSynaptogenix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026APREAprea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/31/2026APREAprea Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$7.003/31/2026APREAprea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $1.203/27/2026ATRAAtara Biotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)2/16/2026APREAprea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPREAprea Therapeutics$290K40.68N/AN/A$1.52 per share0.63ATRAAtara Biotherapeutics$120.77M0.73$6.05 per share1.72($5.34) per share-1.95LITSLite Strategy$65.30M0.67$5.98 per share0.20$4.96 per share0.24TAOXSynaptogenix$300K149.90N/AN/A$2.83 per share2.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPREAprea Therapeutics-$12.60M-$1.98N/AN/AN/A-4,405.59%-96.33%-74.35%5/13/2026 (Estimated)ATRAAtara Biotherapeutics$32.69M$3.123.3352.00N/A27.07%-79.12%87.55%5/21/2026 (Estimated)LITSLite Strategy-$15.94M-$1.33N/AN/AN/AN/A-68.86%-67.48%N/ATAOXSynaptogenix-$28.74M-$17.14N/AN/AN/AN/A-193.08%-144.93%N/ALatest APRE, ATRA, LITS, and TAOX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026ATRAAtara Biotherapeutics-$0.3295N/AN/AN/A$2.90 millionN/A5/13/2026Q1 2026APREAprea Therapeutics-$0.23N/AN/AN/A$0.00 millionN/A3/31/2026Q4 2025TAOXSynaptogenixN/A$1.03N/A$1.03N/A($2.46) million3/16/2026Q4 2025APREAprea Therapeutics-$0.38-$0.32+$0.06-$0.32N/A$0.00 million3/16/2026Q4 2025ATRAAtara Biotherapeutics-$0.68-$0.25+$0.43-$0.36$0.70 million$1.60 million2/17/2026Q2 2026LITSLite StrategyN/A-$0.82N/A-$0.82N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPREAprea TherapeuticsN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ALITSLite StrategyN/AN/AN/AN/AN/ATAOXSynaptogenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPREAprea TherapeuticsN/A5.635.63ATRAAtara BiotherapeuticsN/A0.820.82LITSLite StrategyN/A10.0410.04TAOXSynaptogenixN/A13.9913.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPREAprea Therapeutics34.19%ATRAAtara Biotherapeutics70.90%LITSLite Strategy52.38%TAOXSynaptogenix10.34%Insider OwnershipCompanyInsider OwnershipAPREAprea Therapeutics13.63%ATRAAtara Biotherapeutics41.20%LITSLite Strategy1.60%TAOXSynaptogenix2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPREAprea Therapeutics712.38 million10.70 millionNo DataATRAAtara Biotherapeutics3308.51 million5.01 millionNo DataLITSLite Strategy10036.36 million35.78 millionN/ATAOXSynaptogenix47.47 million7.27 millionN/AAPRE, ATRA, LITS, and TAOX HeadlinesRecent News About These CompaniesTAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI InnovationNovember 18, 2025 | prnewswire.comTradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and SynopsysNovember 11, 2025 | prnewswire.comTAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet FundsNovember 4, 2025 | prnewswire.comTAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI CryptocurrencyOctober 20, 2025 | prnewswire.comTAO Synergies Announces $11 Million Private PlacementOctober 13, 2025 | prnewswire.comTAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)September 22, 2025 | prnewswire.comTAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI EventSeptember 8, 2025 | prnewswire.comTAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open TodayJuly 1, 2025 | prnewswire.comSynaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury StrategyJune 26, 2025 | prnewswire.comSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KXAN AustinJune 26, 2025 | kxan.comKSynaptogenix begins TAO acquisition as part of crypto treasury strategyJune 26, 2025 | uk.investing.comSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KTLAJune 26, 2025 | ktla.comKSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through StakingJune 24, 2025 | prnewswire.comSynaptogenix Unveils TAO-Focused Crypto Treasury PlanJune 10, 2025 | livebitcoinnews.comLSynaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI TokenJune 9, 2025 | prnewswire.comSynaptogenix Inc Ordinary SharesJanuary 3, 2025 | morningstar.comMSynaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet StrengthDecember 20, 2024 | prnewswire.comSynaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comSynaptogenix secures $5 million in preferred stock financingSeptember 13, 2024 | investing.comSynaptogenix Announces $5.0 Million FinancingSeptember 11, 2024 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPRE, ATRA, LITS, and TAOX Company DescriptionsAprea Therapeutics NASDAQ:APRE$0.95 +0.02 (+2.55%) As of 11:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.Atara Biotherapeutics NASDAQ:ATRA$9.99 +1.21 (+13.78%) As of 11:39 AM EasternAtara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.Lite Strategy NASDAQ:LITS$1.20 -0.05 (-3.63%) As of 11:51 AM Eastern This is a fair market value price provided by Massive. Learn more.MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.Synaptogenix NASDAQ:TAOX$5.86 -0.69 (-10.46%) As of 11:51 AM Eastern This is a fair market value price provided by Massive. Learn more.Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
